Osteoporosis

Lancet. 2025 Oct 25;406(10514):2003-2016. doi: 10.1016/S0140-6736(25)01385-6. Epub 2025 Sep 11.

Abstract

Osteoporotic fractures are one of the most common and consequential diseases of advanced ageing and many antifracture therapies are widely available but largely underused. This Seminar presents an updated approach to osteoporosis consultation, drawing upon published evidence and collaborative expert opinion to place the data in a pragmatic and useful context for clinicians. New evidence on osteoporosis screening recommendations, fracture-risk assessment, intervention decisions, nutrition-based therapies, and antiresorptive and anabolic therapies are discussed, along with practical approaches to treatment in the oldest old, those with chronic kidney disease, and patients who continue to fracture despite therapy. Patient safety is emphasised by providing an overview of advice on safe discontinuation of denosumab in those who require it.

Publication types

  • Review

MeSH terms

  • Aged
  • Bone Density Conservation Agents / therapeutic use
  • Denosumab / therapeutic use
  • Humans
  • Osteoporosis* / complications
  • Osteoporosis* / diagnosis
  • Osteoporosis* / drug therapy
  • Osteoporosis* / therapy
  • Osteoporotic Fractures* / etiology
  • Osteoporotic Fractures* / prevention & control
  • Risk Assessment

Substances

  • Bone Density Conservation Agents
  • Denosumab